FDA Approval For Novartis’s Sickle Cell Treatment Adakveo

Gains Nod Ahead Of Global Blood Therapeutics’ Contender

 
• By Andrew McConaghie
Novartis
Adakveo is Novartis' sixth FDA approval of 2019 • Source: Novartis

More from New Products

More from Scrip